By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
Panelists are neutral on Schwab, citing rate sensitivity and structural risks, while acknowledging potential ROE improvement from deposit normalization.
Risk: Rate sensitivity and structural cost of replacing high-cost supplemental funding with organic deposits.
Opportunity: Potential ROE improvement from deposit normalization.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
No less than three analysts raised their price targets on the veteran financial services company.
Two of the three were fairly modest, however.
On Thursday, Charles Schwab (NYSE: SCHW) held its annual Institutional Investor Day, and the following trading session, several analysts issued bullish updates on the stock. Aided by that tailwind at its back, Schwab's shares added nearly 2% in value on Friday.
One notable aspect of Schwab's presentation to its audience was management's raise of certain guidance items. Specifically, it's now modeling annual revenue growth of 14% to 15% for this year, up from 9.5% to 10.5% previously. Net interest margin, a critical metric for many financial companies, is expected to be 3% to 3.1%, up from the preceding forecast of 2.85% to 2.95%.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
By my count, three analysts raised their Schwab price targets on Friday. Barclays' Benjamin Budish now feels the stock is worth $127 per share, up from his previous $117. He maintained his overweight (i.e., buy) recommendation.
His peers, Patrick Moley of Piper Sandler and Bill Katz of TD Cowen, both enacted more modest raises. Moley, who held fast to his neutral rating, added $2 per share, bringing the figure to $105. The more optimistic Katz bumped his target to $109 from $108 while keeping his buy recommendation intact.
Anyone like me who believes the securities markets will remain lively should consider snapping up shares of Schwab. The company is not only a top brokerage in many of those markets but also one of the more diversified businesses in its niche, drawing revenue from many lucrative sources. I have no plans to sell my Schwab stock at all.
Before you buy stock in Charles Schwab, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Charles Schwab wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $468,861! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,445,212!
Now, it’s worth noting Stock Advisor’s total average return is 1,013% — a market-crushing outperformance compared to 210% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 15, 2026. *
Charles Schwab is an advertising partner of Motley Fool Money. Eric Volkman has positions in Charles Schwab. The Motley Fool recommends Barclays Plc and Charles Schwab and recommends the following options: short June 2026 $97.50 calls on Charles Schwab. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"Schwab's guidance hike is a temporary cyclical tailwind that masks the structural risk of deposit sensitivity in a volatile interest rate environment."
The market's 2% reaction to Schwab's guidance hike is a classic 'show me' response. While the revenue growth upgrade to 14-15% is impressive, it is heavily predicated on a specific interest rate environment and client cash sorting stabilization. Investors are cheering the NIM (net interest margin) expansion, but this remains a high-beta play on the yield curve. If the Fed pivots to aggressive cuts faster than the market anticipates, that NIM expansion will evaporate, and the valuation—currently trading at a premium to historical book value—will face a sharp correction. The analyst price target hikes are largely catch-up moves, not fundamental breakthroughs.
If the Fed keeps rates higher for longer to combat sticky inflation, Schwab’s deposit beta will rise, potentially offsetting the NIM gains and pressuring earnings despite the revenue growth.
"Guidance beats expectations, but analyst caution and the absence of structural tailwinds suggest the market is pricing in most of the upside already."
Schwab's guidance raise is real — 14-15% revenue growth and 30bps NIM expansion are material. But the analyst response is tepid: Barclays' $127 target is the only meaningful move; Piper Sandler stays neutral at $105, and Cowen's $109 is barely above Friday's close. The 2% pop reflects relief, not conviction. What's missing: whether this guidance assumes rate stability (it likely does), how much is cyclical vs. structural, and whether the brokerage industry's secular shift to lower-fee models erodes these margins within 18 months.
If rates stay elevated and trading volumes remain robust, Schwab's diversified revenue streams (advisory, lending, trading) could sustain 14-15% growth for 2-3 years, justifying a re-rating to 15-16x forward earnings from today's ~13x.
"N/A"
[Unavailable]
"Durable upside requires sustained NIM improvement and organic growth; without that, the post-day rally risks fading."
Schwab rose on Investor Day optimism, with guidance lifted to 14-15% revenue growth and a net interest margin target of 3.0-3.1%, prompting price-target bumps to 127, 109, and 105. The move looks like a sentiment-driven near-term pop underpinned by a more favorable rate and mix dynamic. Yet the upgrade rests on macro assumptions: NIM expansion, deposit costs, and market activity sustaining upper-band growth. If rates stall or fall, or if trading and asset-gathering slow, those upgrades may prove optimistic. Competitive pressure and fee/expense dynamics add further risk to sustaining multi-quarter outperformance.
The upside hinges on a sustained, favorable rate path and persistent asset growth; if those fade, the stock could reverse despite the day’s optimism.
"The market is underestimating the EPS accretion potential from the normalization of Schwab's funding mix, regardless of minor NIM fluctuations."
Gemini and Claude are obsessing over NIM, but they are ignoring the elephant in the room: Schwab’s massive balance sheet transformation. The real risk isn't just rate sensitivity; it’s the structural cost of replacing high-cost supplemental funding with organic deposits. If client cash sorting continues to normalize, the interest expense relief is a tailwind, but the capital intensity of their banking arm remains a drag on ROE. We are ignoring the potential for a dividend hike or buyback acceleration.
"Deposit normalization is a tailwind to ROE only if deposit beta remains subdued—Gemini flags the cost structure but not the offsetting benefit."
Gemini's capital intensity point is valid, but underspecified. Schwab's ROE drag from banking assets is real—but the deposit beta math matters more. If organic deposits truly normalize (Gemini's assumption), funding costs fall faster than NIM compresses, potentially *improving* ROE despite higher capital requirements. The dividend/buyback angle is worth flagging, but it's secondary to whether deposit beta stays benign. That's the actual hinge.
[Unavailable]
"Schwab's ROE is more likely to stay depressed due to balance-sheet capital needs, making any 'ROE improvement' thesis contingent and fragile."
Gemini's focus on deposit normalization misses the structural cost in Schwab's balance sheet. Even if funding costs fall, the higher capital required to support the banking book keeps ROE under pressure. The real upside—dividends or buybacks—depends on returning excess capital, which isn't guaranteed in a higher-capital, rate-sensitive mix. If deposit beta worsens slower than NIM expands, the 'ROE improvement' thesis is fragile, not a given.
Panelists are neutral on Schwab, citing rate sensitivity and structural risks, while acknowledging potential ROE improvement from deposit normalization.
Potential ROE improvement from deposit normalization.
Rate sensitivity and structural cost of replacing high-cost supplemental funding with organic deposits.